-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 17, 2021, the Danish pharmaceutical company Pharmacosmos A/S (Cosmos Pharmaceuticals) held the Monofi ® China listing conference and announced that its innovative drug Monofi ® (Isomalt Iron 1000) was officially launched in China.
Monofi® was approved in Europe in 2009, and has been approved for the treatment of iron deficiency/iron deficiency anemia in more than 30 countries and regions including the United States and the European Union.
The prevalence of iron deficiency anemia is high, accompanied by a high incidence of many diseases
Iron deficiency anemia (IDA) is an important type of anemia, also known as small cell hypochromic anemia.
Anemia is both a comorbidity and a complication.
Professor Shen Jianxiong
Professor Li Chunde
The advantages of intravenous iron therapy are obvious, and the guidelines recommend wider application
The advantages of intravenous iron therapy are obvious, and the guidelines recommend wider applicationAt present, the treatment of anemia mainly includes oral and intravenous iron.
In orthopedics and other surgical operations, perioperative iron supplementation can not only reduce the degree of anemia, but also reduce the need for blood transfusion in some cases.
The incidence of anemia in patients with chronic kidney disease is high and continues to increase as the disease progresses.
Based on the therapeutic advantages of intravenous iron, the "Chinese Expert Consensus on Intravenous Iron Application" (2019 Edition) recommends strengthening the wider application of intravenous iron, especially for some special patients and patients who are not suitable for oral iron under special circumstances.
High-dose iron injection can correct iron deficiency at one time, which is more convenient and safer
High-dose iron injection can correct iron deficiency at one time, which is more convenient and saferIt is reported that the conventional single dose of existing iron injections is 200 mg, and cannot exceed 3 times a week.
It is worth mentioning that, compared with traditional sucrose iron, Monofi® has a faster onset of action and better safety.
Cosmos is a professional pharmaceutical company headquartered in Denmark, with a worldwide reputation for its unique sugar derivatives platform.
